Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Viridian Therapeutics Inc
VRDNCurrent price
15.92 USD
-0.01 USD (-0.06%)
Last closed
15.81 USD
Company
www.viridiantherapeutics.com
ISIN
US92790C1045
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 706 241 664 USD
Yield for 12 month
-6.85 %
1Y
3Y
5Y
10Y
15Y
VRDN
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Address: 221 Crescent Street, Waltham, MA, United States, 02453
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
41.06 USDP/E ratio
–Dividend Yield
–Current Year
+314 000 USD
Last Year
+1 772 000 USD
Current Quarter
+86 000 USD
Last Quarter
+72 000 USD
Current Year
-1 008 000 USD
Last Year
+1 017 000 USD
Current Quarter
+86 000 USD
Last Quarter
-5 719 000 USD
Key Figures VRDN
1 year
3 years
5 years
10 years
EBITDA
-282 473 984 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-32.15 %
PEG Ratio
–
Return On Equity TTM
-51.88 %
Wall Street Target Price
41.06 USD
Revenue TTM
302 000 USD
Book Value
6.55 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
19.40 %
Dividend Yield
–
Gross Profit TTM
-99 122 000 USD
Earnings per share
-4.32 USD
Diluted Eps TTM
-4.32 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics VRDN
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History VRDN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:15
Payout Ratio
–
Last Split Date
13.11.2020
Stock Valuation VRDN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
3 850.99
Price Sales TTM
5 649.81
Enterprise Value EBITDA
-3.18
Price Book MRQ
3.29
Financials VRDN
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators VRDN
For 52 weeks
11.40 USD
27.20 USD
50 Day MA
22.08 USD
Shares Short Prior Month
9 097 352
200 Day MA
17.28 USD
Short Ratio
7.68
Shares Short
8 750 391
Short Percent
12.55 %
BeatStart